988 Results

People

  1. Lesokhin
    Lesokhin
  2. Landgren
    Landgren
  3. Hassoun
    Hassoun
  4. Mailankody
    Mailankody
  5. Landau
    Landau
  6. Giralt
    Giralt
  7. Korde
    Korde
  8. Hultcrantz
    Hultcrantz
  9. Chung
    Chung
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)
  7. Sloan Kettering Institute Postdocs (292)
  8. Bone Marrow Transplant (289)
  9. Epidemiology and Biostatistics (209)
  10. Biostatistics Service (175)
  1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma
    Journal Article

    Kazandjian, D.; Diamond, B.; Papadimitriou, M.; Hill, E.; Sklavenitis-Pistofidis, R.; Ziccheddu, B.; Blaney, P.; Chojnacka, M.; Durante, M.; Maclachlan, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?
    Review

    Rajeeve, S.; Hoskote, A.; Mailankody, S.
    Seminars in Hematology (2024)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
    Journal Article

    Skerget, S.; Penaherrera, D.; Chari, A.; Jagannath, S.; Siegel, D. S.; Vij, R.; Orloff, G.; Jakubowiak, A.; Niesvizky, R.; Liles, D.; more...
    Nature Genetics (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia
    Research Letter

    Sharma, D.; Ungar, B.; Adalsteinsson, J. A.; Sigurdsson, J. K.; Sharp, K.; Thorsteinsdóttir, S.; Rögnvaldsson, S.; Þórðardóttir, Á R.; Viðarsson, B.; Önundarson, P. T.; more...
    Archives of Dermatological Research (2024)

    Fulltext@MSK | Save
  • Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; McKay, J. T.; Weisel, K. C.; Teipel, R.; Korde, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Ahsan, A.; Mantis, C.; Luo, X.; Zhang, C. C.; Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9
    Meeting Abstract

    Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Raza, M. S.; Acosta, J.; Muller, P.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.; Service, M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save